Prognostic parameters for flare in systemic lupus erythematosus

被引：95

作者：

Mirzayan, MJ ^{[1
]}

Schmidt, RE ^{[1
]}

Witte, T ^{[1
]}

机构：

[1] Med Hsch Hannover, Abt Klin Immunol, D-30625 Hannover, Germany

来源：

RHEUMATOLOGY | 2000年 / 39卷 / 12期

关键词：

SLE; flares; SLEDAI; prognosis;

D O I：

10.1093/rheumatology/39.12.1316

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To characterize prognostic parameters for systemic lupus erythematosus (SLE) flares. Methods. In a prospective study, 120 SLE patients attending our out-patient clinic were evaluated every 3 months for 2 yr. At every visit clinical manifestations and laboratory parameters were assessed and the SLE disease activity index (SLEDAI) was determined. A correlation analysis of the number of flares in the first year and SLEDAI as a marker of disease activity after 1 and 2 yr with several parameters determined at the start of the study was performed. Results. Flares were predicted by erythrocyte sedimentation rate (P = 0.001), anaemia (P = 0.006) and lymphopenia (P = 0.005). The SLEDAI after 1 yr was predicted by the titre of antinuclear antibodies (P = 0.009), antibodies against double-stranded DNA (P = 0.007), lymphopenia (P = 0.007), anaemia (P = 0.0002) and SLEDAI determined at the start of the study (P = 0.001). Conclusions. Anaemia and lymphopenia predict both flares and SLEDAI within the next year of follow-up.

引用

页码：1316 / 1319

页数：4

共 16 条

[1] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].

BOMBARDIER, C ;

GLADMAN, DD ;

UROWITZ, MB ;

CARON, D ;

CHANG, CH .

ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640

[2] Morbidity and mortality in systemic lupus erythematosus during a 5-year period -: A multicenter prospective study of 1,000 patients [J].

Cervera, R ;

Khamashta, MA ;

Font, J ;

Sebastiani, GD ;

Gil, A ;

Lavilla, P ;

Aydintug, AO ;

Jedryka-Góral, A ;

de Ramón, E ;

Fernández-Nebro, A ;

Galeazzi, M ;

Haga, HJ ;

Mathieu, A ;

Houssiau, F ;

Ruiz-Irastorza, G ;

Ingelmo, M ;

Hughes, GRV .

MEDICINE, 1999, 78 (03) :167-175

[3] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].

Hochberg, MC .

ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725

[4]

HOCHBERG MC, 1990, RHEUM DIS CLIN N AM, V16, P617

[5] ANTI-DNA ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS - DIAGNOSTIC AND THERAPEUTIC GUIDE [J].

HUGHES, GRV ;

COHEN, SA ;

CHRISTIAN, CL .

ANNALS OF THE RHEUMATIC DISEASES, 1971, 30 (03) :259-+

[6] A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value [J].

Jacobsen, S ;

Petersen, J ;

Ullman, S ;

Junker, P ;

Voss, A ;

Rasmussen, JM ;

Tarp, U ;

Poulsen, LH ;

Hansen, GV ;

Skaarup, B ;

Hansen, TM ;

Podenphant, J ;

Halberg, P .

CLINICAL RHEUMATOLOGY, 1998, 17 (06) :478-484

[7] OUTCOME IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY OF PATIENTS FROM A DEFINED POPULATION [J].

JONSSON, H ;

NIVED, O ;

STURFELT, G .

MEDICINE, 1989, 68 (03) :141-150

[8]

LEBLANC BAEW, 1994, J RHEUMATOL, V21, P2239

[9] IMMUNE-COMPLEXES, COMPLEMENT, AND ANTI-DNA IN EXACERBATIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) [J].

LLOYD, W ;

SCHUR, PH .

MEDICINE, 1981, 60 (03) :208-217

[10] COURSE AND PROGNOSTIC VALUE OF SYSTEMIC LUPUS-ERYTHEMATOSUS DISEASE-ACTIVITY INDEX IN BLACK CARIBBEAN PATIENTS [J].

NOSSENT, JC .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (01) :16-21

← 1 2 →